Citius Pharmaceuticals (NASDAQ:CTXR) Stock Rating Upgraded by Zacks Research

Citius Pharmaceuticals (NASDAQ:CTXR) was upgraded by Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

CTXR has been the subject of a number of other reports. D. Boral Capital reissued a “buy” rating and set a $6.00 price target on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Citius Pharmaceuticals in a research report on Monday. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $5.00.

Citius Pharmaceuticals Price Performance

Shares of NASDAQ CTXR opened at $0.58 on Tuesday. Citius Pharmaceuticals has a 1 year low of $0.48 and a 1 year high of $2.48. The stock has a market cap of $15.92 million, a P/E ratio of -0.27 and a beta of 1.05. The firm has a 50-day moving average of $0.77 and a 200 day moving average of $0.89.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.67). The company had revenue of $1.67 million for the quarter, compared to the consensus estimate of $10.23 million. Research analysts expect that Citius Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. XTX Topco Ltd raised its holdings in Citius Pharmaceuticals by 572.8% in the fourth quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after buying an additional 91,196 shares during the last quarter. Heights Capital Management Inc. purchased a new position in Citius Pharmaceuticals in the fourth quarter worth about $622,000. Asset Advisory Group Inc. purchased a new position in Citius Pharmaceuticals in the fourth quarter worth about $46,000. Finally, NewEdge Advisors LLC purchased a new position in Citius Pharmaceuticals in the second quarter worth about $40,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

Key Citius Pharmaceuticals News

Here are the key news stories impacting Citius Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on Citius Pharmaceuticals and maintained a $4.00 price target, signaling meaningful upside potential from current levels. Citius Pharmaceuticals’ (CTXR) “Buy” Rating Reaffirmed at HC Wainwright
• Neutral Sentiment: The firm also issued updated earnings estimates for FY2026 and FY2027, with expectations for ongoing losses, including FY2026 EPS of ($1.87) and FY2027 EPS of ($0.81). While these forecasts show improvement over time, they still reflect a pre-profit company. HC Wainwright earnings estimate updates for Citius Pharmaceuticals
• Neutral Sentiment: HC Wainwright’s quarterly projections for Citius Pharmaceuticals remain negative across the forecast period, including Q3 2026 EPS of ($0.36), Q4 2026 EPS of ($0.25), Q1 2027 EPS of ($0.28), Q2 2027 EPS of ($0.20), Q3 2027 EPS of ($0.19), and Q4 2027 EPS of ($0.16). HC Wainwright quarterly earnings estimates for Citius Pharmaceuticals

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.